Report Analyzes Product Pipeline of DIAsource ImmunoAssays SA

DIAsource ImmunoAssays SA Market
DIAsource ImmunoAssays SA Market

A recent market research report added to the vast research report portfolio of is focused on a niche sector – the product pipeline analysis of DIAsource ImmunoAssays SA, a diagnostic company that manufactures, develops, and markets a range of clinical diagnostics products directed towards the fields of infectious diseases and endocrinology. The report is titled “DIAsource ImmunoAssays SA – Product Pipeline Analysis, 2017 Update.”

DIAsource ImmunoAssays SA (DIAsource), which was previously known as BioSource Europe SA, is a subsidiary of Anteo Diagnostics Ltd. The product offerings of the company span from antibodies, immunoassays, instruments, to RUO products. The company’s portfolio of antibodies include thyroid stimulating hormone, adiponectin, adrenocorticotropic hormone, parathyroid hormone, calcitonin, osteocalcin, carcino embryonic antigen, aggrecan, placental lactogen and alpha-fetoprotein.

The set of instruments offered by DIAsource includes shaker, automated system, washer, ELISA reader, and neptune instrument. The other important fields that the company offers its products to include fertility, salt and cardiovascular balance, auto-immunity, and gastrointestinal metabolism. The company markets its products in Belgium as well as other countries. It’s headquarter is located it Louvain-La-Neuve, Belgium.

The report covers an analytical overview of the detailed business profile of the company and includes data such as business description, key services and products, key facts about the company, company’s key employees, competitors, subsidiaries, locations, and recent developments. The report also presents an analytical account of all the pipeline products that are under development for the company.

For Sample Copy, click here:

The report analyzes the pipeline products on the basis of criteria such as indication, equipment type, stage of development, and status of trial. Detailed data related to all the products in the company’s pipeline with information related to device class, pipeline territory, stage of development, indications, regulatory path, applications, and the estimated date of launch in the market is included in the report. A thorough description of products in the pipeline, along with their functions and technical specification has also been included in the report.

This report is a comprehensive source of analysis, market information, and actionable intelligence regarding on DIAsource’s portfolio of products under development. The report is meant to act as a source of data that can enhance the process of decision making and allow readers to formulate effective counter strategies to gain an upper hand.

Wherever applicable, the report presents an overview of the status of ongoing trials with data such as the name of the trial, trial’s objective, design of the trial, sponsor, phase of the trial, and an estimate of the start date and the end date of the trial.

The thorough 28-page report is aimed at helping readers in developing business strategies by gaining a detailed understanding of the key trends and developments that are driving the sector of medical devices, their pipelines, and the technology landscape. Using the detailed understanding of the company’s portfolio through the report, readers can develop effective marketing, product development, and sales strategies. The report can also allow readers to formulate research and development strategies that promise excellent returns.

The report data can allow the reader to achieve sustainable and promising returns from in-licensing and out-licensing opportunities by identifying the products that are capable of providing robust returns. The data can allow companies to gain insights regarding mergers and acquisitions that can lead to most promising results in terms of product portfolio expansion. The report helps identify the vendors with a strong product portfolio, helping them create effective counter-strategies for achieving a competitive advantage over peers.

Leave a Reply